// App-Quantinova.ai

2305 : Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda

Researchers

Presenter

  • Ashutosh D. Wechalekar

Principal Investigators

  • Giovanni Palladini

  • Giampaolo Merlini

  • Raymond L. Comenzo

  • Arnaud Jaccard

  • NamPhuong Tran

  • Huiling Pei

  • Sandra Y. Vasey

  • Brenda Tromp

  • Brendan M. Weiss

  • Jessica Vermeulen

  • Efstathios Kastritis

Medical Centers

  • Kings College London, London, United Kingdom

  • Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Department of Molecular Medicine, University of Pavia,Pavia,Italy

  • Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy

  • Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

  • Centre Hospitalier Universitaire and Reference Center for AL Amyloidosis, Limoges, France

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Research and Development, Titusville, NJ

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, Leiden, Netherlands

  • Janssen Research & Development, Leiden, Netherlands

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, ATHENS, Greece

Locations

  • United Kingdom

  • Italy

  • United States

  • France

  • Netherlands

  • Greece

Companies

  • JB Medical Ltd.

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • AL Amyloidosis

  • Amyloid disease

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Hyaluronidase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • daratumumab Intravenous

  • Bortezomib

  • Sparsentan

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT03201965

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved